Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 13/20 | 0.71 |
| ▸ | INSR | P06213 | 10/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 5/20 | 0.44 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | NEK2 | P51955 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclopropane SCHEMBL16966197 | 0.93 | ALK (0.73) | ALKINSRKCNH2IGF1REGFR | |
| SCHEMBL886496 | 0.92 | ALK (0.70) | ALKINSRKCNH2IGF1REGFR | |
| SCHEMBL885875 | 0.92 | ALK (0.70) | ALKINSRKCNH2IGF1REGFR | |
| SCHEMBL886701 | 0.91 | ALK (0.70) | ALKINSRKCNH2IGF1REGFR | |
| SCHEMBL886323 | 0.88 | ALK (0.78) | ALKINSRKCNH2IGF1REGFR | |
| SCHEMBL885835 | 0.88 | ALK (0.78) | ALKINSRKCNH2IGF1RAXL | |
| SCHEMBL886199 | 0.83 | ALK (1.00) | ALKINSRKCNH2IGF1REGFR | |
| SCHEMBL886105 | 0.83 | ALK (0.57) | ALKINSRKCNH2ZAP70PTK2 | |
| SCHEMBL886104 | 0.83 | ALK (0.70) | ALKINSR | |
| SCHEMBL886360 | 0.79 | ALK (0.78) | ALKINSRKCNH2EGFRZAP70 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |